Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1184-1198

  Daniel Mullins, C ^a   Kuznik, Andreas ^a   Shaya, Fadia T ^a   Obeidat, Nour A ^a   Levine, Andrew R ^a   Liu, Larry Z ^b   Wong, Winston ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b PFIZER INC   (United States)

^c CareFirst BlueCross BlueShield   (United States)

Author keywords

cost effectiveness analysis; linezolid; methicillin resistance; nosocomial pneumonia; vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG INDICATION; FEMALE; HEALTH CARE PLANNING; HOSPITAL BILLING; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONTE CARLO METHOD; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; CROSS INFECTION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33748582610     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.016     Document Type: Article

References (49)

1. Myrianthefs P.M., Kalafati M., Samara I., and Baltopoulos G.J. Nosocomial pneumonia. Crit Care Nurs Q 27 (2004) 241-257
2. Craven D.E., Palladino R., and McQuillen D.P. Healthcare-associated pneumonia in adults: Management principles to improve outcomes. Infect Dis Clin North Am 18 (2004) 939-962
3. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P., and National Nosocomial Infections Surveillance System. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 27 (1999) 887-892
4. Rello J., Ollendorf D.A., Oster G., et al., VAP Outcomes Scientific Advisory Group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122 (2002) 2115-2121
5. Chen Y.Y., Chou Y.C., and Chou P. Impact of nosocomial infection on cost of illness and length of stay in intensive care units. Infect Control Hosp Epidemiol 26 (2005) 281-287
6. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
7. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
8. Abramson M.A., and Sexton D.J. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?. Infect Control Hosp Epidemiol 20 (1999) 408-411
9. Rubin R.J., Harrington C.A., Poon A., et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 5 (1999) 9-17
10. Kopp B.J., Nix D.E., and Armstrong E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 38 (2004) 1377-1382
11. Vincent J.L., Bihari D.J., Suter P.M., et al., EPIC International Advisory Committee. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 274 (1995) 639-644
12. Kuehnert M.J., Hill H.A., Kupronis B.A., et al. Methicillin-resistant Staphylococcusaureus hospitalizations, United States. Emerg Infect Dis 11 (2005) 868-872
13. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 31 (2003) 481-498
14. Bishara J., Pitlik S., Samra Z., et al. Co-trimoxazole-sensitive, methicillinresistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 9 (2003) 1168-1169
15. Monnet D.L., MacKenzie F.M., Lopez-Lozano J.M., et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 10 (2004) 1432-1441
16. Tiemersma E.W., Bronzwaer S.L., Lyytikainen O., et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 10 (2004) 1627-1634
17. Lanet J.C., Chevret S., Durand-Zaleski I., et al. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: Results of a multicenter study. Arch Intern Med 163 (2003) 181-188
18. Cooper B.S., Stone S.P., Kibbler C.C., et al. Isolation measures in the hospital management of methicillin resis tant Staphylococcus aureus (MRSA): Systematic review of the literature. BMJ 329 (2004) 533
19. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis 7 (2001) 178-182
20. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
21. Kuroda M., Ohta T., Uchiyama I., et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357 (2001) 1225-1240
22. Cui L., Ma X., Sato K., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 (2003) 5-14
23. Beringer P.M., Wong-Beringer A., and Rho J.P. Economic aspects of antibacterial adverse effects. PharmacoEconomics 13 (1998) 35-49
24. Available at:. Drugs@FDA. A Catalog of FDA Approved Drug Products. Accessed (July 27, 2005). http://www.accessdata.fda.gov/scripts/cder/drugsatfda
25. Moellering R.C. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 138 (2003) 135-142
26. Ament P.W., Jamshed N., and Horne J.P. Linezolid: Its role in the treatment of gram-positive, drug-resistant bacte rial infections. Am Fam Physician 65 (2002) 663-670
27. Anderegg T.R., Sader H.S., Fritsche T.R., et al. Trends in linezolid susceptibility patterns: Report from the 2002 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 26 (2005) 13-21
28. Micromedex Health Care Series (November 17, 2004). http://www.thomsonhc.com.
29. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
30. Rubinstein E., Isturiz R., Standiford H.C., et al. Worldwide assessment of linezolid's clinical safety and toler ability: Comparator-controlled phase III studies. Antimicrob Agents Chemother 47 (2003) 1824-1831
31. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 51 Suppl 2 (2003) 645-653
32. McKinnon P.S., Sorensen S.V., Liu L.Z., and Itani K.M. Impact of linezolid on economic outcomes and determi nants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40 (2006) 1017-1023
33. Plosker G.L., and Figgitt D.P. Linezolid: A pharmacoeconomic review of its use in serious gram-positive infections. PharmacoEconomics 23 (2005) 945-964
34. Machado A.R., Arns Cda C., Follador W., and Guerra A. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis 9 (2005) 191-200
35. Shorr A.F., Susla G.M., and Kollef M.H. Linezolid for treatment of ventilator associated pneumonia: A cost effective alternative to vancomycin. Crit Care Med 32 (2004) 137-143
36. Finkler S.A. The distinction between cost and charges. Ann Intern Med 96 (1982) 102-109
37. Shwartz M., Young D.W., and Siegrist R. The ratio of costs to charges: How good a basis for estimating costs?. Inquiry 32 (1995) 476-481
38. Drug Topics Red Book (2004), Thompson PDR, Montvale, NJ
39. Haddadin A.S., Fappiano S.A., and Lipsett P.A. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 78 (2002) 385-392
40. Weinstein M.C. From cost-effectiveness ratios to resource allocation: Where to draw the line?. In: Sloan F.A. (Ed). Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies (1995), Cambridge University Press, New York, NY 77-97
41. [published correction appears in Am J Respir Crit Care Med. 2000;163:1759-1760]. Fagon J., Patrick H., Haas D.W., et al., Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 161 (2000) 753-762
42. Available at:. US Dept of Health and Human Services, Agency for Health Care Research and Quality. Guidance for Using the AHRQ Quality Indicators for Hospital-Level Public Reporting or Payment. Accessed (March 3, 2005). http://www.qualityindicators.ahrq.gov/downloads/technical/gi_guidance.pd f
43. Bassin A.S., and Niederman M.S. New approaches to prevention and treatment of nosocomial pneumonia. Semin Thorac Cardiovasc Surg 7 (1995) 70-77
44. Wiblin R.T., and Wenzel R.P. Hospital acquired pneumonia. Curr Clin Top Infect Dis 16 (1996) 194-214
45. Niederman M.S., McCombs J.S., Unger A.N., et al. The cost oftreating communityacquired pneumonia. Clin Ther 20 (1998) 820-837
46. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
47. McHugh C.G., and Riley L.W. Risk factors and costs associated with methicillinresistant Staphylococcus aureus blood stream infections. Infect Control Hosp Epidemiol 25 (2004) 425-430
48. Kritchevsky S.B., Braun B.I., Wong E.S., et al. Impact of hospital care on incidence of bloodstream infection: The evaluation of processes and indicators in infection control study. Emerg Infect Dis 7 (2001) 193-196
49. Krumholz H.M., Chen J., Rathore S.S., et al. Regional variation in the treatment and outcomes of myocardial in farction: Investigating New England's advantage. Am Heart J 146 (2003) 242-249